ACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aurora Cannabis Inc (ACB) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock shows weak financial performance, neutral trading sentiment, and no significant positive catalysts. While analysts maintain a Buy rating, the lack of recent positive news, weak technical indicators, and declining net income suggest holding off on investment until stronger signals or improvements emerge.
The technical indicators for ACB are mostly bearish. The MACD is slightly positive but expanding, suggesting weak momentum. The RSI is neutral at 41.051, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 3.254 and resistance at 3.535. Overall, the technical outlook is not favorable for a buy.
Analysts maintain a Buy rating and highlight Aurora's strong position in international medical cannabis markets with higher gross margins. Revenue increased by 6.79% YoY in the latest quarter.
Net income dropped significantly by 93.63% YoY, and EPS fell by 94.23% YoY. There is no recent news or significant trading activity from insiders, hedge funds, or politicians. The stock has a 40% chance of declining slightly in the next week and month.
In Q3 2026, Aurora Cannabis reported a revenue increase of 6.79% YoY to $94,191,000. However, net income dropped by 93.63% YoY to $1,820,000, and EPS fell by 94.23% YoY to 0.03. Gross margin improved significantly by 69.91% YoY to 5.93%, but overall profitability remains weak.
Analysts from Canaccord maintain a Buy rating with a reduced price target of C$9 from C$10. They highlight Aurora's strong position in international medical cannabis markets and higher-margin opportunities abroad.
